Company news

First Tracks Biotherapeutics, Inc. news

Latest news releases, newest first.

View company

First Tracks Biotherapeutics Announces $200 Million Private Placement

October 15, 2026

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

October 12, 2026

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

October 11, 2026

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

August 26, 2026

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

May 21, 2026

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

April 20, 2026

Decks